Literature DB >> 18362664

Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.

Malik Y Kahook1, Robert J Noecker.   

Abstract

PURPOSE: To evaluate corneal and conjunctival changes after chronic, once-daily dosing of travoprost preserved with sofZia, latanoprost preserved with 0.02% benzalkonium chloride (BAK), or preservative-free artificial tears.
METHODS: Thirty New Zealand white rabbits were randomized to receive once-daily instillation of travoprost with sofZia, latanoprost, or preservative-free artificial tears in 1 eye. Corneal epithelial changes were evaluated by transmission electron microscopy and graded on a standard scale by 2 masked observers. Conjunctival inflammation was evaluated by light microscopy after hematoxylin and eosin staining. Lymphocytes were counted in the epithelium and superficial stroma by 2 masked observers and compared among groups.
RESULTS: Corneal tissue treated with preservative-free artificial tears and travoprost with sofZia revealed similar changes under transmission electron microscopy (P = 0.53). Significantly more corneal epithelial damage was noted with latanoprost than travoprost with sofZia (P = 0.0001). The number of lymphocytes in the conjunctival epithelium and stroma was significantly lower in eyes treated with travoprost with sofZia than eyes treated with latanoprost (P = 0.0001). The number of conjunctival lymphocytes was similar among conjunctival specimens exposed to travoprost with sofZia and preservative-free artificial tears (P = 0.65).
CONCLUSIONS: Once-daily dosing of travoprost with sofZia produced significantly fewer corneal changes and less conjunctival inflammation than latanoprost preserved with BAK. Corneal and conjunctival changes noted with travoprost with sofZia were similar to those induced by preservative-free artificial tears. Glaucoma medication with high levels of BAK may cause more deleterious effects on the ocular surface than non-BAK-preserved medications. Human studies are needed to better understand the clinical effects of different preservative types and concentrations on the ocular surface.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362664     DOI: 10.1097/ICO.0b013e31815cf651

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  44 in total

1.  Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy.

Authors:  Ai-Wei Liu; Lin-Yang Gan; Xiang Yao; Jian Zhou
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

3.  Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells.

Authors:  Dorota Pozarowska; Piotr Pozarowski; Zbigniew Darzynkiewicz
Journal:  Cytometry B Clin Cytom       Date:  2010-03       Impact factor: 3.058

4.  A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension.

Authors:  David A Godfrey; Lee S Peplinski; Jeanette A Stewart; William C Stewart
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

Authors:  Su Khoh-Reiter; Bart A Jessen
Journal:  BMC Ophthalmol       Date:  2009-07-28       Impact factor: 2.209

6.  Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2009-06-02

7.  First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2010-05-14

8.  Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits.

Authors:  Abayomi B Ogundele; Guangming Li; Joel J Ellis
Journal:  Clin Ophthalmol       Date:  2010-02-18

9.  Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay.

Authors:  Hong Liang; Christophe Baudouin; Marie-Odile Faure; Grégory Lambert; Françoise Brignole-Baudouin
Journal:  Mol Vis       Date:  2009-08-25       Impact factor: 2.367

10.  Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Henny J M Beckers; Jan Sag Schouten; Carroll A B Webers
Journal:  Clin Ophthalmol       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.